FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.

| More


Take Action

Read our statement in response to the FDA decision, and our testimony presented at the FDA hearing on Avastin.

If you are a woman living with advanced hereditary breast cancer please take our metastatic breast cancer survey and help us advocate for more options for treating hereditary breast cancer.

The cancer drug Avastin has been studied as a treatment for advanced breast and ovarian cancer. Not all women with advanced cancer respond equally to the medication. The FDA has decided that the benefits of Avastin do not outweigh the risks for women with advanced breast cancer and the agency has removed Avastin from the list of approved breast cancer therapies. While FORCE respects the FDA's decision, we are disappointed with this outcome. There are women with advanced breast cancer for whom Avastin appears to work well. FORCE has prepared a statement in response to the FDA recent ruling.

FORCE's concerns

  • FORCE is concerned that this label change will restrict access to the medication for women who are currently on and benefiting from the drug.
  • We are concerned that this change will restrict access for women who are newly diagnosed with metastatic breast and ovarian cancer who might benefit from the medication but will not be presented with it as a treatment option.
  • Further, we are concerned that insurance companies may use the FDA decision to restrict reimbursement even for those women who are currently on and responding to the medication.

More research needed

More research is needed to better determine which portion of breast cancer patients most benefit from Avastin. The decision of whether or not a woman with stage IV breast cancer should have access to Avastin should be made after discussion and consideration of benefits vs. risks with her health care team.

Learn about our accomplishments and how you can help.

Recognize a Loved One

The FORCE Research Advocate Training (FRAT) Program is a basic educational course aimed at preparing people to become engaged in research advocacy on behalf of the hereditary breast and ovarian cancer community.

Personal Fundraising

FORCE is proud of the progress we have made in support, research and advocacy that better the lives or our community.

FORCE:Facing Our Risk of Cancer Empowered